Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Hansen Ree

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Acta Oncologica (Stockholm, Sweden)|August 9, 2022
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine studyAnne Hansen Ree, Gunhild M Mælandsmo, Kjersti Flatmark, et al.
Oncotarget|May 5, 2016
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancerSebastian Meltzer, Erta Kalanxhi, Helga Helseth Hektoen, et al.
Angiogenesis|August 12, 2011
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic disseminationMarie Grøn Saelen, Kjersti Flatmark, Sigurd Folkvord, et al.
Critical Reviews in Oncology/Hematology|January 28, 2015
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapiesAnne Hansen Ree, Kjersti Flatmark, Marie Grøn Saelen, et al.
Radiation Oncology (London, England)|September 29, 2012
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinomaMarie Grøn Saelen, Anne Hansen Ree, Alexandr Kristian, et al.
Clinical & Experimental Metastasis|November 6, 2003
The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cellsAse Bratland, Erlend Ragnhildstveit, Kristin Bjørnland, et al.
BMC Cancer|May 12, 2021
Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancerHanna Abrahamsson, Sebastian Meltzer, Vidar Nyløkken Hagen, et al.
Radiation Oncology (London, England)|August 5, 2006
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibitionKjersti Flatmark, Ragnhild V Nome, Sigurd Folkvord, et al.
The Lancet. Oncology|April 10, 2010
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 studyAnne Hansen Ree, Svein Dueland, Sigurd Folkvord, et al.
International Journal of Molecular Sciences|April 28, 2023
Energy Metabolism Is Altered in Radioresistant Rectal CancerCroí E Buckley, Xiaofei Yin, Sebastian Meltzer, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Acta Oncologica (Stockholm, Sweden)|August 9, 2022
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine studyAnne Hansen Ree, Gunhild M Mælandsmo, Kjersti Flatmark, et al.
Oncotarget|May 5, 2016
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancerSebastian Meltzer, Erta Kalanxhi, Helga Helseth Hektoen, et al.
Angiogenesis|August 12, 2011
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic disseminationMarie Grøn Saelen, Kjersti Flatmark, Sigurd Folkvord, et al.
Critical Reviews in Oncology/Hematology|January 28, 2015
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapiesAnne Hansen Ree, Kjersti Flatmark, Marie Grøn Saelen, et al.
Radiation Oncology (London, England)|September 29, 2012
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinomaMarie Grøn Saelen, Anne Hansen Ree, Alexandr Kristian, et al.
Clinical & Experimental Metastasis|November 6, 2003
The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cellsAse Bratland, Erlend Ragnhildstveit, Kristin Bjørnland, et al.
BMC Cancer|May 12, 2021
Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancerHanna Abrahamsson, Sebastian Meltzer, Vidar Nyløkken Hagen, et al.
Radiation Oncology (London, England)|August 5, 2006
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibitionKjersti Flatmark, Ragnhild V Nome, Sigurd Folkvord, et al.
The Lancet. Oncology|April 10, 2010
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 studyAnne Hansen Ree, Svein Dueland, Sigurd Folkvord, et al.
International Journal of Molecular Sciences|April 28, 2023
Energy Metabolism Is Altered in Radioresistant Rectal CancerCroí E Buckley, Xiaofei Yin, Sebastian Meltzer, et al.
Pageof 11